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Acute renal failure (ARF) in critically ill patients is associated
with high mortality. Optimal method and dose of continuous
renal replacement therapy could improve survival in these
patients. We studied the hypothesis that an increase in
dialysis dose obtained by continuous veno-venous
hemodiafiltration (CVVHDF) is associated with a better
survival than continuous veno-venous hemofiltration (CVVH)
among critically ill patients with ARF. In a prospective
randomized trial, these two methods were compared in
patients undergoing renal replacement therapy in two
intensive care units (ICUs). The patients had either CVVH
(1–2.5 l/h replacement fluid) or continuous CVVHDF (1–2.5 l/h
replacement fluidþ 1–1.5 l/h dialysate) according to their
body weight. 28- and 90-day mortalities, renal recovery, and
duration of ICU stay were the main outcome measures. Two
hundred and six patients were randomized from October
2000 to December 2003. Twenty-eight-day survivals (%)
were, respectively, 39 and 59 (P¼ 0.03) in the CVVH and
CVVHDF groups. Three months survivals (%) were,
respectively, 34 and 59 (P¼ 0.0005) in the CVVH and CVVHDF
groups. Apache II score, age, baseline blood urea nitrogen,
and hemodiafiltration (hazard ratio 0.59, 95% confidence
interval 0.40–0.87; P¼ 0.008) were independent predictors of
survival at 90 days. Renal recovery rate among survivors (71
versus 78% in the CVVH and CVVHDF groups respectively,
P¼ 0.62) was not affected by the type of renal replacement
therapy. These results suggest that increasing the dialysis
dose especially for low molecular weight solutes confers a
better survival in severely ill patients with ARF.
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Acute renal failure (ARF) occurs frequently in intensive care
unit (ICU) patients and critically ill patients with ARF
present an overall mortality ranging from 37 to 70%.1,2
Intermittent hemodialysis was the main renal replacement
therapy until the end of the 1970s when continuous renal
replacement therapies (CRRTs) (continuous hemofiltration
and hemodialysis) were introduced.2 Despite the necessity of
permanent anticoagulation and subsequently increased risk
of bleeding, these continuous treatments have been gaining
popularity among nephrologists and intensive care specialists
as there is less treatment-induced cardiovascular instability
than with intermittent hemodialysis. Solute removal occurs
in continuous therapies by convection, diffusion, and
adsorption.3 Continuous veno-venous hemofiltration
(CVVH) works by convection, meaning that a proportion
of plasma water and solutes are carried across the membrane
by a hydrostatic pressure gradient. Convection is particularly
efficient in removing middle molecular weight solutes.
Continuous veno-venous hemodialysis (CVVHD) works
mainly by diffusion. The dialysate flow runs countercurrently
through the filter and diffusive solute removal results in
decreased solute concentration in the blood compartment
along the length of the hemodialyser. Diffusion is more
efficient for removing small molecular weight solutes. When
both mechanisms are combined, CRRT is labelled continuous
veno-venous hemodiafiltration (CVVHDF). This therapy is
particularly advocated for highly catabolic patients as it is
assumed that improved small molecules clearance is of
greater benefit to the patient.3 There is some evidence that
mortality is inversely correlated to the dialysis dose4 and that
a Kt/V higher than 1.0 per session has a significant impact on
the mortality.5 Recently, a randomized prospective study
demonstrated that the survival rate in patients with ARF and
treated by CVVH was enhanced by increasing the ultrafiltra-
tion rate from 25 to 35 ml/kg/h.6 Although these results were
not confirmed in another trial,7 one may question whether
this positive effect on mortality is due to a better removal of
inflammatory mediators by increased clearance of medium-
sized molecules or simply to a better overall dialysis dose.
Adding a dialysis compartment to CVVH will mainly
increase the small solutes clearance without affecting the
removal of middle molecules such as inflammatory media-
tors. We therefore undertook a study to determine whether
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increasing the dialysis dose by adding a dialysis flow rate to
CVVH for intensive care patients with ARF will affect their
prognosis.
RESULTS
Patient characteristics
Between October 2000 and December 2003, 371 patients with
ARF were treated by CRRTs in our institution. Two hundred
and six patients (56%) were enrolled. The plan of the study is
shown in Figure 1. The seven patients who were not treated
because of rapid improvement of their renal function (n¼ 3)
or death before implementation of treatment (n¼ 4) and 19
patients who died within the first 24 h of the intervention
were included in the intent-to-treat analysis.
Demographics and clinical characteristics are shown in
Table 1. The two groups did not differ in their baseline
characteristics, except for mean pre-treatment plasma creati-
nine level, which was significantly higher in the CVVHDF
group. One hundred and forty-three (69%) patients were
recruited in the medical ICU. Sixty-eight (33%) patients were
known to have chronic renal failure before the present insult,
51% were known to have a normal serum creatinine before
this hospitalization, and 16% were thought to have normal
renal function (based on their age and/or absence of known
comorbidities) before this episode of acute renal injury.
Procedural data
Within the first 24 h, most of the treatment prescribed was
delivered to the patients in both groups (Table 2). At 48 h
after implementation of CRRT, mean urea reduction ratio in
the CVVH and CVVHDF groups was 40 and 50%, respec-
tively (Po0.009). Mean creatinine reduction ratios were
38 and 46% for the CVVH and CVVHDF groups,
respectively (Po0.014).
Patient outcomes
Survival at 28 days was, respectively, 39 and 59% (P¼ 0.03)
in the CVVH and CVVHDF groups. Survival at 90 days was,
respectively, 34 and 59% (P¼ 0.0005) in the CVVH and
CVVHDF groups (see Figure 2).
Excluding the 26 untreated or moribund patients, survival
at 28 days was, respectively, 44 and 64% (P¼ 0.003) in the
CVVH and CVVHDF groups. Survival at 90 days was,
respectively, 38 and 64% (P¼ 0.0004) in the CVVH and
CVVHDF groups.
Between days 28 and 90, five patients died in the CVVH
group, whereas no deaths were noted in the CVVHDF group.
Causes of death were: intractable heart failure in a heart
transplant patient, sudden death occurring after complete
renal recovery in one patient, multiorgan failure in one
patient, and dialysis withdrawal for palliative care in two
patients. Of these five patients, two were still treated by CRRT
at the time of death and two had previous chronic renal
impairment before the acute renal injury.
At 28 days, Apache II score (hazard ratio (HR) 1.05, 95%
confidence interval (CI) 1.02–1.08), age (HR 1.02, 95% CI
1.00–1.04), baseline blood urea nitrogen (BUN) (HR 0.98,
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Figure 1 | Trial profile.
Table 1 | Clinical and laboratory characteristics of patients at
baseline
CVVH group
(n=102)
CVVHDF group
(n=104)
Age (years) 65712 62715
Male gender (%) 65 57
Weight (kg) 73715 73720
Diagnosis of renal failure
(medical/trauma/surgical)
66/11/25 77/5/22
Specific etiologies of renal failure (n)
Sepsis 34 37
Volume depletion or
intraoperative ischemia
16 20
Cardiogenic shock or cardiac
arrest
20 12
Nephrotoxic drugs/contrast
media
5 8
Rhabdomyolysis 1 2
Malignant hypertension 1 4
Myeloma kidney 1 —
Multifactorial 24 21
APACHE II score 2679 2479
SOFA score 1075 975
Sepsis (%) 56 64
Oliguria (%) 33 41
Creatinine (mmol/l) 3887170 4687318*
BUN (mmol/l) 29714 30714
BUN, blood urea nitrogen; CVVH, continuous veno-venous hemofiltration;
CVVHDF, continuous veno-venous hemodiafiltration; SOFA, sequential organ failure
assessment.
Data are given in mean7s.d.
*Po0.03.
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(95% CI 0.97–0.99), and hemodiafiltration (HR¼ 0.65 (95%
CI 0.43–0.96)) were independent predictors of death in a Cox
multivariate analysis model. With baseline serum creatinine
instead of baseline BUN, hemodiafiltration was just not
statistically significant (HR¼ 0.71 (95% CI: 0.48–1.06)).
At 90 days, Apache II score (HR¼ 1.06 (95% CI:
1.03–1.08)), age (HR¼ 1.02 (95% CI 1.0–1.04)), baseline
BUN (HR 0.98, (95% CI 0.97–0.99)), and hemodiafiltration
(HR¼ 0.59 (95% CI 0.40–0.87)) remained independent
predictors of survival (Table 3). When baseline BUN was
replaced by baseline serum creatinine in the model,
hemodiafiltration remained a significant predictive factor
(HR¼ 0.59 (95% CI 0.38–0.93)).
Of the 101 patients who were still alive at 28 days, 12%
remained on dialysis, of whom three were still treated in an
ICU setting by CRRT and nine by intermittent hemodialysis.
Of the 95 patients who survived at 90 days, 75% had
recovered their previous renal function. Among those with
permanent chronic renal impairment at 90 days, four (two in
each group) remained on dialysis.
Type of renal replacement therapy did not affect
significantly the rate of renal recovery at 90 days among
survivors (71 versus 78% in the CVVH and CVVHDF
groups, respectively, P¼ 0.62). The only finding which
differentiated between those who recovered renal function
from those with persistent renal impairment was the
prevalence of previous CRF, which was significantly lower
in the former group (33 versus 68%, P¼ 0.006).
Duration of the ICU stay was longer in the CVVHDF
group (Table 3), although this was not statistically significant
(P¼ 0.06). This difference did not persist when the analysis
was restricted to survivors (data not shown), and this
reflected likely the lower early mortality in the patients
treated by CVVHDF.
Side effects
CRRT was well tolerated in our patients.
Occurrence of CRRT-associated complications such as
bleeding was similar between the two groups, with only one
major episode of bleeding in each group.
Filter clotting (filter lasting less than 24 h) did not differ
between the two groups (1.171.7 versus 1.372.5 filter/
person/day, P¼ 0.97).
DISCUSSION
Our results showed that adding a dialysis dose to CVVH had
an impact on mortality in critically ill patients with ARF. At
28 days, survival was 59% in the CVVHDF group compared
to the 39% observed in the CVVH group and this difference
remained highly significant at 90 days. ARF occurs com-
monly in critically ill patients and is associated with high
mortality ranging from 37 to 70%.2,8 Patients with sepsis are
especially prone to develop ARF in the context of multiorgan
failure and the mortality may be as high as 80–90%.9,10 Thus,
it is important to find the optimal renal replacement therapy
for these patients. The use of biocompatible membranes,
daily intermittent hemodailysis, and continuous hemofiltra-
tion with an ultrafiltration rate of X35 ml/kg/h have been
shown in randomized trials to reduce the mortality of ARF
patients.6,11–13 Although there is no consensus as to the
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Figure 2 | Kaplan–Meier analysis of survival rates in the two
groups.
Table 2 | Intervention data
CVVH group
(n=102)
CVVHDF group
(n=104)
Mean prescribed ultrafiltration
dose (ml/kg/h)
2575 2476
Mean prescribed dialysis dose
(ml/kg/h)
— 1875
Bicarbonate replacement fluid (%) 58 52
Delivered dose during first 24 h (%) 87711 83716
T1 after 24 h CRRT 36.670.7 36.770.7
CRRT-free days at day 28 (days) 22 (9) 23 (7)
Mechanical ventilation-free
days at day 28 (days)
19 (10) 21 (9)
Cumulative NA dose (mg) 35 (1–172) 11 (0–107)
Duration of ICU stay (days) 6 (2–10) 8 (4–16)
CRRT, continuous renal replacement therapy; CVVH, continuous veno-venous
hemofiltration; CVVHDF, continuous veno-venous hemodiafiltration; ICU, intensive
care unit; NA, noradrenaline; T1, temperature.
Table 3 | Results of Cox’s proportional hazards model (90-day
survival)
Variable Unadjusted HR P-value Adjusted HR P-value
Age 1.01 (0.99–1.03) 0.07 1.02 (1.00–1.04) 0.01
Gender 0.80 (0.54–1.18) 0.26 0.70 (0.44–1.09) 0.12
Weight 1.00 (0.99–1.01) 0.91 1.0 (0.99–1.01) 0.71
Diagnosis
Surgical 1 0.32 1 0.12
Trauma 1.48 (0.68–3.19) 0.43 1.88 (0.84–4.19) 0.19
Medical 1.21 (0.76–1.92) 1.40 (0.85–2.29)
Sepsis 1.53 (1.02–2.30) 0.04 1.30 (0.50–1.20) 0.24
Baseline BUN 0.98 (0.97–0.99) 0.02 0.98 (0.97–0.99) 0.008
CVVHDF vs CVVH 0.40 (0.31–0.73) 0.001 0.59 (0.40–0.87) 0.008
APACHE II score 1.07 (1.04–1.09) 0.001 1.06 (1.03–1.08) 0.001
BUN, blood urea nitrogen; CI, confidence interval; CVVHDF, continuous venovenous
hemodiafiltration; CVVH, continuous venovenous hemofiltration; HR, hazard ratio.
Data are given with 95% CI.
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optimal dose of dialysis, better control of uremia was shown
to be beneficial in these patients.8 However, no difference in
the survival of patients with ARF was found in another trial,
where early implementation of treatment and high volume
hemofiltration (median 48 ml/kg/h) was compared with late
treatment and low volume filtration (median 19 ml/kg/h).7
These conflicting results are probably explained by a
difference in patients populations. Although our population
had more sepsis, and with a probably later implementation of
CRRT (as judged by its baseline BUN level) than in the study
conducted by Ronco et al., we also noted an improvement in
patients who received a higher dose of dialysis. Most of the
difference in survival between the two groups occurred in the
first 20 days and an improved control of aezotemia in the
early course of their renal insufficiency in critically ill patients
may be primordial. Adding ultrafiltration and dialysis flow
rates provided a mean ‘ultrafiltration’ dose of approximately
42 ml/kg/h in the CVVHDF group, which should be
comparable to the higher ultrafiltration rates used within
the two previous trials.6,7 The main difference with these
trials was the method of CRRT. Instead of increasing the
ultrafiltration rate, we chose to improve the clearance of
small molecules by adding dialysis solution. Indeed, im-
proved control of aezotemia may explain this decrease in
mortality. Previously, in a prospective cohort of patients with
severe ARF, high-volume hemofiltration up to 100 l/day was
associated with a lower death rate than expected.14 high-
volume hemofiltration (8 l/h) during 4 h has been shown to
reverse intractable septic shock in some patients.15 Removal
of toxic mediators owing to the high membrane permeability
and the ultrafiltration flow may explain this positive effect on
survival. However, the increment of dialysis in our group
treated by CVVHDF was due to the addition of dialysis flow,
which increased mainly the clearance of small molecules such
as urea and has a negligible effect on middle molecules
clearance.16
Other techniques such as daily intermittent hemodialysis
and slow extended dialysis have been used successfully in ICU
patients with ARF.12,17 These methods also had a negligible
effect on the clearance of middle molecules. Slow extended
dialysis seems to be associated with equivalent cardiovascular
stability and solute control as CRRT.18
A faster resolution of renal impairment was noted among
patients treated with daily dialysis compared with inter-
mittent dialysis.12 Renal recovery did not differ among
survivors in our two groups, but owing to our sample size, a
type I error can not be excluded. Further trials powered for
that particular issue are necessary to determine whether a
beneficial effect on renal recovery is observed with increased
dose of CRRT. Duration of ICU stay did not differ in our two
groups.
Our trial has some limitations. At randomization, a
slightly higher (but not statistically significant) Apache II
score in the CVVH group may contribute to the poorer
survival seen in this group. Although the difference was not
statistically significant, more patients with cardiogenic shock
or cardiac arrest were randomized to the CVVH group and
patients with this diagnosis are known to have a particularly
ominous prognosis. Excluding these patients does, however,
not change the results of our survival analysis. It is
improbable that the higher baseline creatinine in the
CVVHDF group, which may reflect a more profound renal
impairment, could also have contributed to this difference in
the survival. Serum creatinine is a poor marker of ARF in
ARF10 and when it was used instead of baseline BUN in our
multivariate model, the results did not change substantially.
Effectively received dialysis treatments are usually lower than
those prescribed in ICU patients.19 During the first 24 h,
received dialysis and ultrafiltration doses were above 80% of
what was prescribed in both groups and we have to assume
that ultrafiltration and dialysis daily doses were similar
throughout the whole ICU stay. One may argue that our
CVVH group had a high mortality owing to underdialysis
but the mean prescribed 25 ml/kg/h is a usual dose prescribed
previously in our unit and as well widely throughout the
ICU.19 Heat loss is known to occur in patients treated
with CRRT and that may contribute to mortality.20 We could
not find a difference in body temperature between the groups
after the first treatment day (see Table 3). For logistic reasons,
there was no treatment blinding, but it is unlikely that the
method of RRT may have biased our colleagues in the ICUs.
Lastly, we did not compare diuretic use in our two groups
and diuretic use was found to be detrimental in a cohort
study of critically ill patients.21 This observation was however,
not confirmed in a recently published randomized trial
studying the use of diuretics in patients with ARF.22
In summary, these results suggest that patients treated
with CRRT may benefit of an increased dialysis dose,
especially for low molecular weight solutes. This translates
in a better survival in severely ill patients with ARF.
MATERIALS AND METHODS
Patients
Our study population comprised patients treated in the medical and
surgical ICUs of Geneva University Hospitals. They were eligible for
extra-renal replacement therapy if they fulfilled the following
inclusion criteria: oliguria (urine output o200 ml/12 h) despite
fluid resuscitation and intravenous diuretic treatment, and/or
aezotemia (BUN 430 mmol/l) with urine output o1500 ml/12 h.
Exclusion criteria were the following: prerenal failure (reversi-
bility of oliguria/uremia with fluid administration or with
improvement of cardiac output), postrenal failure (on renal
ultrasound examination and/or antegrade or retrograde contrast
studies if high clinical suspicion), suspicion of glomerular disease (if
high clinical suspicion and compatible urinalysis and/or serologic
tests), end-stage renal failure (baseline serum creatinine
4300 mmol/l or creatinine clearance o20 ml/min), and patients
on angiotensin-converting enzyme inhibitors (24 h temporary
exclusion owing to possibility of ACE inhibitors induced anaphy-
lactoid reaction with the polyacrylonitrile AN69 filter). The severity
of illness was determined on the day of the first renal replacement
treatment with the help of sequential organ failure assessment and
APACHE II scores.
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At enrolment, demographic data, APACHE II score, and etiology
of renal failure were recorded. Causes of renal failure were simplified
as medical, surgical, and trauma for the purposes of statistical
analysis. Diagnosis of sepsis was made by the ICU team according to
the American College of Chest Physicians/Society of Critical Care
Medicine Consensus Conference.23
Previous chronic renal failure was diagnosed if the patients were
known to have an abnormal serum creatinine level (488 and
4106mmol/l for women and men, respectively) before the present
hospitalization.
To be eligible, patients have fulfilled the inclusion criteria. They
or their relatives were asked for their consent to participate in the
trial. The study protocol was approved by the Geneva University
Hospitals Ethics Committee.
Study design: Patients were randomized to either CVVH or
CVVHDF. A randomization list was generated by computer, in
random blocks of four and six patients, and corresponding
treatment allocation cards were placed in consecutively numbered
opaque envelopes. Each time a patient was enrolled in the study, the
next available envelope was opened by the nephrologist on call, and
the allocated treatment option was communicated to the treatment
team. Blinding was impossible for logistic reasons.
Intervention
A dual lumen venous catheter was inserted through a central vein.
Renal replacement therapy was initiated and continued for 48 h, and
then followed by 24 h observation if clinically possible. On account
of increasing BUN and/or persisting oliguria, renal replacement
therapy was resumed for another 48 h. Inotropic support was
prescribed when mean arterial pressure was o60 mm Hg and
cardiac index was o2.5 l/min/m2.
Dialysis treatment was performed by pump-driven machines
(Prisma, Hospal-Gambro) with fluid balance systems and multiflow
100 polyacrylonitrile, 0.9 m2 AN 69 membrane (Hospal-Gambro).
Replacement fluid was administered in the predilution mode. Blood
flow was maintained between 100 and 125 ml/min. Bicarbonate
replacement fluid was provided for patients with severe liver
impairment, hyperlactacidemia, or severe hemodynamic instability.
Otherwise, lactate replacement fluid was used.
CVVH: Ultrafiltration flow rate (1–2.5 l/h) was determined
according to patient’s estimated urea distribution volume (60% of
their body weight at enrolment), so that this estimated volume
could be cleared within 24 h, for example, a 80-kg patient will have
an ultrafiltration flow rate of 2 l/h. For the purposes of simplifica-
tion, hourly ultrafiltration flow rate was rounded off to the upper
500 ml level within the interval from 1 to 2.5 l.
CVVHDF: In addition to the ultrafiltration rate, dialysate
flow rate was added between 1 and 1.5 l/h for patients weighing
less or more than 70 kg. Owing to the effluent bag capacity, 2.5 l
was the maximum hourly ultrafiltration rate if patients were
randomized in the CVVHDF group and received also 1.5 l/h of
dialysate. Heparin was administered during renal replacement
therapy in the absence of bleeding, severe thrombocytopenia, or
impaired liver function. In which case, heparin was replaced by
periodic flushing with saline. Any bleeding episodes were recorded.
Invasive monitoring was requested if patients required inotropic
support.
The filter was changed daily during the first 48 h. Protein-rich
(42g/kg per day) and energy-rich (30–35 kcal/day) nutritional
support was provided. Recovery of renal function was based on
assessment of urine output and biochemical data to determine
whether the patient needed further renal replacement therapy
(absence of all criteria for implementing CRRT, urine output¼ 1 ml/
kg/h over 24 h, neutral fluid balance).
Renal replacement therapy was stopped when there was extreme
hypotension unresponsive to inotropic support or irreversible severe
lactic acidosis.
Statistical analysis
The primary outcomes were survival at 28 and 90 days. Analysis was
performed using the intent-to-treat approach. Analyses that
excluded untreated patients and those who died within the 24 h
after onset of CRRT were also performed.
The secondary outcomes were: renal recovery (mean duration of
ARF) and length of ICU stay.
Parametric and non-parametric tests were used to check for
significant differences between demographic and baseline character-
istics of study groups. Significant P-values were o0.05.
Survival and renal recovery were assessed with the Kaplan–Meier
method and a Cox’s proportional hazards model was used for
controlling for possible pre-randomization confounding factors.
The variables analyzed in this model were similar to those analyzed
in the trial by Ronco et al.6 (age, weight, gender, cause of renal
failure, APACHE II score, presence of sepsis, BUN at start of CRRT,
and method of CRRT).
Sample size: With an expected death rate of 60% in this
population and assuming a 25% decrease in mortality, 90 patients
per group were required to have a 80% power with an ao 0.05.
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